Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study

Am J Ther. 2018 Nov/Dec;25(6):e767-e768. doi: 10.1097/MJT.0000000000000774.

Authors

Sarbajit Mukherjee¹, Sami Ibrahimi¹, Michael Machiorlatti², Darwin Roman³, Rabia Saleem³, Ayesha Hassan³, Allison Baxley⁴, Sara Vesely⁵, Raid Aljumaily¹

Affiliations

¹ Division of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
² Department of Biostatistics and Epidemiology, University of Oklahoma, Oklahoma City, Oklahoma.
³ Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
⁴ Department of Clinical Pharmacy Services, University of Oklahoma, Oklahoma City, Oklahoma.
⁵ Department of Biostatisctics and Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

PMID: 29746291
DOI: 10.1097/MJT.0000000000000774

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / economics
Antineoplastic Agents, Immunological / administration & dosage*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / economics
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Female
Humans
Kaplan-Meier Estimate
Lung Neoplasms / drug therapy*
Lung Neoplasms / mortality
Male
Middle Aged
Nivolumab / administration & dosage*
Nivolumab / adverse effects
Nivolumab / economics

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Nivolumab
pembrolizumab